| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
COO | COO and General Counsel | General Counsel
1 company
Patrick O'Brien is COO at ARWR. Patrick O'Brien's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $32.6M at current prices.
Historically, Patrick O'Brien's trades have earned a strong insider score of 76/100 across 10 rated trades. Over a 12-month horizon, 77.8% of those trades were profitable, with an average 12-month return of +2.9%.
The ARWR filings lean toward selling, a net 416,492 shares.
Patrick O'Brien has 20 Form 4 filings on record from January 2016 to January 2026, all as COO at Arrowhead Pharmaceuticals (ARWR), 2016–2026.
The 75 reported transactions were 50 open-market sales, 11 gifts, 10 stock awards and 3 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 11 sales worth about $20.7M.
The largest open-market sale was 90,000 shares of ARWR at an average $88.46 on February 8, 2021, about $8.0M. Twelve months later ARWR was down 41%.
All 3 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | ARWR Arrowhead Pharmaceuticals, Inc. | COO | Sell10b5-1 | 49,493 | $63.11 | $3,123,349.43 | -9.4% | -4.3% | - | |
| Jan 7, 2025 | ARWR Arrowhead Pharmaceuticals, Inc. | COO and General Counsel | Sell10b5-1 | 37,184 | $19.80 | $736,058.62 | -6.6% | -47.9% | +234.0% | |
| Jan 5, 2024 | ARWR Arrowhead Pharmaceuticals, Inc. | COO and General Counsel | Sell10b5-1 | 33,190 | $34.36 | $1,140,362.32 | -6.7% | -26.7% | -44.4% | |
| Jan 5, 2023 | ARWR Arrowhead Pharmaceuticals, Inc. | COO and General Counsel | Sell | 15,000 | $37.39 | $560,850.00 | -3.5% | -31.9% | -4.0% | |
| Jan 3, 2023 | ARWR Arrowhead Pharmaceuticals, Inc. | COO and General Counsel | Sell | 17,500 | $38.33 | $670,802.17 | -4.6% | -33.6% | -17.0% | |
| Jan 5, 2022 | ARWR Arrowhead Pharmaceuticals, Inc. | General Counsel | Sell | 32,500 | $61.72 | $2,005,875.26 | -8.5% | -19.6% | -38.4% | |
| Feb 8, 2021 | ARWR Arrowhead Pharmaceuticals, Inc. | General Counsel | Sale+OE | 90,000 | $88.46 | $7,961,240.32 | -23.5% | -25.2% | -41.0% | |
| Jan 6, 2021 | ARWR Arrowhead Pharmaceuticals, Inc. | General Counsel | Sell | 25,000 | $72.41 | $1,810,345.62 | -7.9% | - | - | |
| Jan 6, 2020 | ARWR Arrowhead Pharmaceuticals, Inc. | General Counsel | Sell | 14,625 | $60.12 | $879,260.67 | -5.4% | - | - | |
| May 28, 2019 | ARWR Arrowhead Pharmaceuticals, Inc. | General Counsel | Sell | 30,000 | $24.88 | $746,400.00 | -12.9% | - | - |